EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

• Published in: Journal of steroid biochemistry and molecular biology Vol. 69; no. 1; pp. 51 - 84
• Main Authors: Labrie, Fernand, Labrie, Claude, Bélanger, Alain, Simard, Jacques, Gauthier, Sylvain, Luu-The, Van, Mérand, Yves, Giguere, Vincent, Candas, Bernard, Luo, Shouqi, Martel, Céline, Singh, Shankar Mohan, Fournier, Marc, Coquet, Agnès, Richard, Virgile, Charbonneau, Ronald, Charpenet, Gilles, Tremblay, André, Tremblay, Gilles, Cusan, Lionel, Veilleux, Raymonde
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford Elsevier Ltd 01-04-1999; Elsevier Science
• Subjects: Adjuvant; Animals; Antineoplastic agents; Biological and medical sciences; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Chemotherapy; Cholesterol; EM-652; EM-800; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Endometrium - drug effects; Endometrium - metabolism; Estrogen Antagonists - administration & dosage; Estrogen Antagonists - metabolism; Estrogen Antagonists - pharmacology; Female; Humans; Mammary Glands, Animal - drug effects; Mammary Glands, Animal - metabolism; Medical sciences; Neoadjuvant; Osteoporosis; Pharmacology. Drug treatments; Piperidines - administration & dosage; Piperidines - pharmacology; Prevention; Pure antiestrogen; Risk reduction; SCH 57050; SCH 57068; Selective estrogen receptor modulator (SERM); Triglycerides; Uterine cancer; EM-800; Pure antiestrogen; Risk reduction; Neoadjuvant; Breast cancer; Triglycerides; Cholesterol; Prevention; Osteoporosis; SCH 57068; Selective estrogen receptor modulator (SERM); Adjuvant; Uterine cancer; EM-652; SCH 57050; Antineoplastic agent; Human; Antiestrogen; Oral administration; Antihormone; Review; Malignant tumor; Biological activity; Female genital diseases; Mammary gland diseases; Antagonism; Animal; Uterine diseases; Mammary gland; Mechanism of action; Non steroid compound; Endometrium; Hormonal receptor
• ISSN: 0960-0760; 1879-1220
• DOI: 10.1016/S0960-0760(99)00065-5

Breast cancer is the most frequent cancer in women while it is the second cause of cancer death. Estrogens are well recognized to play the predominant role in breast cancer development and growth and much efforts have been devoted to the blockade of estrogen formation and action. The most widely used therapy of breast cancer which has shown benefits at all stages of the disease is the use of the antiestrogen Tamoxifen. This compound, however, possesses mixed agonist and antagonist activity and major efforts have been devoted to the development of compounds having pure antiestrogenic activity in the mammary gland and endometrium. Such a compound would avoid the problem of stimulation of the endometrium and the risk of endometrial carcinoma. We have thus synthesized an orally active non-steroidal antiestrogen, EM-652 (SCH 57068) and the prodrug EM-800 (SCH57050) which are the most potent of the known antiestrogens. EM-652 is the compound having the highest affinity for the estrogen receptor, including estradiol. It has higher affinity for the ER than ICI 182780, hydroxytamoxifen, raloxifene, droloxifene and hydroxytoremifene. EM-652 has the most potent inhibitory activity on both ER
α and ER
β compared to any of the other antiestrogens tested. An important aspect of EM-652 is that it inhibits both the AF1 and AF2 functions of both ER
α and ER
β while the inhibitory action of hydroxytamoxifen is limited to AF2, the ligand-dependent function of the estrogen receptors. AF1 activity is constitutive, ligand-independent and is responsible for mediation of the activity of growth factors and of the ras oncogene and MAP-kinase pathway. EM-652 inhibits Ras-induced transcriptional activity of ER
α and ER
β and blocks SRC-1-stimulated activity of the two receptors. EM-652 was also found to block the recruitment of SRC-1 at AF1 of ER
β, this ligand-independent activation of AF1 being closely related to phosphorylation of the steroid receptors by protein kinase. Most importantly, the antiestrogen hydroxytamoxifen has no inhibitory effect on the SRC-1-induced ER
β activity while the pure antiestrogen EM-652 completely abolishes this effect, thus strengthening the need to use pure antiestrogens in breast cancer therapy in order to control all known aspects of ER-regulated gene expression. In fact, the absence of blockade of AF2 by hydroxytamoxifen could explain why the benefits of tamoxifen observed up to 5 years become negative at longer time intervals and why resistance develops to tamoxifen. EM-800, the prodrug of EM-652, has been shown to prevent the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat, a well-recognized model of human breast cancer. It is of interest that the addition of dehydroepiandrosterone, a precursor of androgens, to EM-800, led to complete inhibition of tumor development in this model. Not only the development, but also the growth of established DMBA-induced mammary carcinoma was inhibited by treatment with EM-800. An inhibitory effect was also observed when medroxyprogesterone was added to treatment with EM-800. Uterine size was reduced to castration levels in the groups of animals treated with EM-800. An almost complete disappearance of estrogen receptors was observed in the uterus, vaginum and tumors in nude mice treated with EM-800. EM-652 was the most potent antiestrogen to inhibit the growth of human breast cancer ZR-75-1, MCF-7 and T-47D cells in vitro when compared with ICI 182780, ICI 164384, hydroxytamoxifen, and droloxifene. Moreover, EM-652 and EM-800 have no stimulatory effect on the basal levels of cell proliferation in the absence of E2 while hydroxytamoxifen and droloxifene had a stimulatory effect on the basal growth of T-47D and ZR-75-1 cells. EM-652 was also the most potent inhibitor of the percentage of cycling cancer cells. When human breast cancer ZR-75-1 xenografts were grown in nude mice, EM-800 led to a complete inhibition of the stimulatory effect of estrogens in ovariectomized mice while tamoxifen was less potent and even stimulated the growth of the tumors in the absence of estrogens, thus illustrating the stimulatory effect of tamoxifen on breast cancer growth. When incubated with human Ishikawa endometrial carcinoma cells, EM-800 had no stimulatory effect on alkaline phosphatase activity, an estrogen-sensitive parameter. Raloxifene, droloxifene, hydroxytoremifene and hydroxytamoxifen, on the other hand, all stimulated to various extent, the activity of this enzyme. The stimulatory effect of all four compounds was blocked by EM-800, thus confirming their estrogenic activity in human endometrial tissue. When administered to ovariectomized animals, EM-800 prevents bone loss, the effect on bone mineral density, trabecular bone volume, and trabecular separation being 5–10 times more potent than raloxifene. EM-800 lowers serum cholesterol and triglyceride levels in the rat as well as in women. In a Phase II study performed in patients with breast cancer showing failure on tamoxifen, 1 patient had a complete response while 5 patients had a partial response and stable disease for at least three months has been observed in an additional 13 patients for a total of 19 positive responses out of 43 evaluable patients (44.2%). No significant secondary effect related to the drug was observed. A phase 3 international clinical trial is currently being performed in tamoxifen failure patients where EM-800 (SCH 57050) is compared to Arimidex. The detailed information obtained at the preclinical level with EM-652 or EM-800 indicates that these orally active compounds are highly potent and pure antiestrogens in the mammary gland and endometrium while they prevent bone loss and lower serum cholesterol and triglyceride levels. Preclinical and clinical data clearly suggest the interest of studying this compound in the neoadjuvant and adjuvant settings and, most importantly, for the prevention of breast and uterine cancer in which settings they should provide additional benefits on bone and lipids.